Hympavzi boosts quality of life for hemophilia patients in trial
Hympavzi (marstacimab) reduced bleeding rates and improved quality of life in adults and adolescents with hemophilia A or B…
Articles by Andrea Lobo, PhD
Liver rupture leads to hemophilia B diagnosis in newborn: Case report
A newborn in China was diagnosed with hemophilia B after a ruptured liver caused significant abdominal bleeding, according to…
Doctors warn eye bleeding can be first sign of hemophilia A
A 32-year-old man was diagnosed with hemophilia A after a minor injury caused disproportionate right eye bleeding, with a…
Spinal stenosis may be complication of aging in hemophilia patients
Symptomatic spinal stenosis — the narrowing of spaces within the spinal canal, which can put pressure on the spinal cord…
Immune tolerance induction lowers treatment costs, if successful
Successful immune tolerance induction (ITI) — a type of treatment that aims to re-educate the immune system to prevent the…
Beqvez shows long-term safety, efficacy in adults with hemophilia B
Beqvez (fidanacogene elaparvovec-dzkt), a one-time gene therapy developed by Pfizer that was formerly approved for hemophilia B, was…
Final guidance issued for Altuvoct as severe hemophilia A treatment
The National Institute for Health and Care Excellence (NICE) has issued a final guidance recommending the use of Altuvoct…
Hemophilia patients’ bone health screening rates low at US HTCs
Despite high rates of bone health issues in hemophilia and von Willebrand disease (VWD), the routine use of DEXA…
On Alhemo, patients without inhibitors report better life quality
Prophylactic, or preventive, treatment with Alhemo (concizumab) is associated with better quality of life and a lower treatment burden…
Bleeding, blood clot-related events in US tied to acquired hemophilia
About 30% of people hospitalized due to acquired hemophilia have a bleeding event, while 17% report a thrombotic, or…